Method for enhancing cognition or inhibiting cognitive decline
OwnerScott Malstrom, John J. Byrnes +1inventors
InventorsScott Malstrom, John J. Byrnes, Michelle Wolfe
Life of this patent
Estimating the term…
Abstract
A method for enhancing cognition or inhibiting cognitive decline in a subject comprises selecting a Ca2+ channel blocker that is effective, when administered intravenously to an animal in a nontoxic amount, to increase NF-κB expression in the brain of the animal; and administering the selected Ca2+ channel blocker to the subject, via a systemic route that affords an adequate therapeutic window for cognition-enhancing or cognitive decline-inhibiting effectiveness of the selected Ca2+ channel blocker, in an amount within the therapeutic window. The selected Ca2+ channel blocker can be, for example, tiapamil or a pharmaceutically acceptable salt or prodrug thereof.
Claims30
A method for enhancing cognition or inhibiting cognitive decline in a subject, comprising:
- selecting a Ca2+ channel blocker that is effective, when administered intravenously to an animal in a nontoxic amount, to increase NF-κB expression in the brain of the animal;
- and
- administering the selected Ca2+ channel blocker to the subject, via a systemic route that affords an adequate therapeutic window for cognition-enhancing or cognitive decline-inhibiting effectiveness of the selected Ca2+ channel blocker, in an amount within the therapeutic window.
A method for enhancing cognition or inhibiting cognitive decline in a subject having a cognitive deficit disorder or neurodegenerative condition that is not ameliorated by induction of autophagy, the method comprising systemically administering a therapeutically effective amount of tiapamil or a pharmaceutically acceptable salt or prodrug thereof to the subject.
A method for enhancing cognition or inhibiting cognitive decline in a normotensive subject having a cognitive deficit disorder or neurodegenerative condition that is not ameliorated by induction of autophagy, the method comprising administering a Ca2+ channel blocker to the subject, via a systemic route that affords an adequate therapeutic window for cognition-enhancing or cognitive decline-inhibiting effectiveness of the Ca2+ channel blocker, in an amount within the therapeutic window.
A method for enhancing cognition or inhibiting cognitive decline in a subject, comprising systemically administering (a) a Ca2+ channel blocker to the subject in a cognition-enhancing or cognitive decline-inhibiting effective amount, and (b) an agent that counteracts a non-brain-specific adverse side-effect of the Ca2+ channel blocker.
A therapeutic combination comprising a Ca2+ channel blocker and an antihypotensive agent.
Dependencies are inferred from the claim text.